Merck four-week hep C regimen with Gilead's Sovaldi comes up short

(Reuters) - An attempt by Merck & Co to shorten hepatitis C treatment to just four weeks by adding Gilead Sciences Inc's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy due to a high rate of relapses, according to interim data from a midstage study.

from Reuters: Most Read Articles http://ift.tt/1uUs7Tx http://www.reuters.com